-+ 0.00%
-+ 0.00%
-+ 0.00%

NRx Pharma says FDA completes first-cycle review of preservative-free ketamine ANDA

PUBT·08/07/2026 20:01:50
Listen to the news
NRx Pharma says FDA completes first-cycle review of preservative-free ketamine ANDA
  • NRx Pharmaceuticals set an Aug. 10 investor call to discuss the FDA’s completed first-cycle review of its ANDA for preservative-free ketamine.
  • The update follows the company’s earlier disclosure on the review outcome, with focus on the remaining regulatory path and commercialization plans.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608071601PRIMZONEFULLFEED9806152) on August 07, 2026, and is solely responsible for the information contained therein.